16 March 2020 - Teva Pharmaceuticals USA and Celltrion Healthcare today announced that Herzuma (trastuzumab-pkrb) for Injection, a biosimilar to Herceptin, is now available in the United States with the same indications as the reference product.

The Wholesale Acquisition Cost (WAC) for Herzuma 150 mg is $1,402.50 and Herzuma 420 mg is $3,927, which is a 10% discount to the WAC of Herceptin. Actual costs to individual patients and providers for Herzuma are anticipated to be lower than WAC because WAC does not account for additional rebates and discounts that may apply. 

Savings on out-of-pocket costs may vary depending on the patient’s insurance payer and eligibility for participation in the assistance program.

Read Teva Pharmaceuticals press release